Microbix Biosystems says client presenting product results at 2026 PASCV

Microbix Biosystems (MBXBF) announces that one of its clients is presenting results of Microbix made quality assessment products that help enable full-process quality management of molecular assays to detect human papillomavirus at 2026 PASCV. 2026 PASCV is the annual meeting and principal gathering of the Pan American Society for Clinical Virology, taking place in Clearwater Beach, Florida April 29 to May 1, 2026. The three-day event unites industry leaders and specialists committed to advancing the science and practice of viral diagnostics with a program presenting cutting-edge research, practical insights and real-world applications. Microbix will not be attending or exhibiting at 2026 PASCV due to budget and scheduling constraints. At 2026 PASCV, a Microbix client is presenting its poster titled “Performance evaluation of Microbix HPV swabs on the Alinity m HR HPV.” Authored by Mark M. Sasaki and Danijela Lucic of Molecular Diagnostics at Abbott with acknowledged support from Microbix staff, the poster discusses the evaluation and performance results of dry swab samples prepared by Microbix for five HPV genotypes, for use in test verification studies on the Alinity m platform. The results demonstrated 100% detection, strong reproducibility, tight standard deviations, and room temperature stability for 12 days after sample preparation.